TR200401601T4 - Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri - Google Patents

Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri

Info

Publication number
TR200401601T4
TR200401601T4 TR2004/01601T TR200401601T TR200401601T4 TR 200401601 T4 TR200401601 T4 TR 200401601T4 TR 2004/01601 T TR2004/01601 T TR 2004/01601T TR 200401601 T TR200401601 T TR 200401601T TR 200401601 T4 TR200401601 T4 TR 200401601T4
Authority
TR
Turkey
Prior art keywords
estrogen receptor
salt forms
receptor modulators
selective estrogen
specific salt
Prior art date
Application number
TR2004/01601T
Other languages
English (en)
Inventor
A. Cain Gary
O. Cann Reginald
A. Teleha Christopher
K. Murphy Denette
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Publication of TR200401601T4 publication Critical patent/TR200401601T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Bu bulus, seçici estrojen reseptörü modülatörleri olarak, 3-[4(1,2-difenil-but-1-enil)-fenil]-akrilik asit gibi trifeniletilen türevlerinin yeni tuz biçimlerine iliskindir. Bu bulus, ayni zamanda, aralarinda, meme, rahim, yumurtalik, prostat ve kolon kanseri, osteoporoz, kalp-damar hastaligi ve selim çogalma bozuluklari bulunan estrojenle uyarilan hastaliklarin iyilestirilmesi ve /veya engellenmesi için yöntemler ve bunlarin yanisira bu bulusun bilesiklerinin farmasötik bilesimlerini de temin etmektedir.
TR2004/01601T 2000-04-05 2001-04-05 Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri TR200401601T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19458000P 2000-04-05 2000-04-05

Publications (1)

Publication Number Publication Date
TR200401601T4 true TR200401601T4 (tr) 2004-08-23

Family

ID=22718126

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01601T TR200401601T4 (tr) 2000-04-05 2001-04-05 Seçici estrojen reseptörü modülatörleri olarak trifeniletilen türevlerinin özel tuz biçimleri

Country Status (12)

Country Link
US (1) US6417394B2 (tr)
EP (1) EP1268387B1 (tr)
JP (1) JP2004507452A (tr)
AT (1) ATE269291T1 (tr)
AU (2) AU5319101A (tr)
CA (1) CA2403263A1 (tr)
DE (1) DE60103867T2 (tr)
DK (1) DK1268387T3 (tr)
ES (1) ES2222988T3 (tr)
PT (1) PT1268387E (tr)
TR (1) TR200401601T4 (tr)
WO (1) WO2001077055A2 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417169A2 (en) 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
EP1692127B1 (en) 2003-10-08 2008-07-02 Smithkline Beecham Corporation Triphenylethylene compounds as selective estrogen receptor modulators
US7196119B2 (en) * 2003-10-21 2007-03-27 The Regents Of The University Of California Development of new selective estrogen receptor modulators
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
EP1951217A4 (en) * 2005-11-22 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
WO2009120999A2 (en) * 2008-03-28 2009-10-01 Olema Pharmaceuticals, Inc. Use of an endoxifen prodrug for treatment of breast cancer
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
CN1275911A (zh) * 1997-08-15 2000-12-06 杜克大学 一种预防或治疗雌激素依赖性疾病及失调的方法

Also Published As

Publication number Publication date
DE60103867T2 (de) 2005-06-30
DK1268387T3 (da) 2004-10-18
EP1268387A2 (en) 2003-01-02
EP1268387B1 (en) 2004-06-16
ES2222988T3 (es) 2005-02-16
ATE269291T1 (de) 2004-07-15
AU5319101A (en) 2001-10-23
JP2004507452A (ja) 2004-03-11
US20020004496A1 (en) 2002-01-10
DE60103867D1 (de) 2004-07-22
WO2001077055A2 (en) 2001-10-18
CA2403263A1 (en) 2001-10-18
WO2001077055A3 (en) 2002-05-30
US6417394B2 (en) 2002-07-09
AU2001253191B2 (en) 2006-03-02
PT1268387E (pt) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2003016270A3 (en) Selective estrogen receptor modulators
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
AU2001231710A1 (en) Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
IL153406A0 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
WO2001056990A3 (en) Pyridine derivates as potentiators of glutamate receptors
IL145941A0 (en) Compositions and methods for cancer treatment by selectively inhibiting vegf
WO2002096868A3 (en) Preparation of 17-phenyl- 18, 19, 20- trinor-pgf2a and its derivatives
GEP20074197B (en) 5ht2c receptor modulators
MXPA02009773A (es) Derivados de indolin-2-ona y su uso como ligandos de receptores de ocitocina.
EP0911321A3 (en) Compounds for the treatment of osteoporosis
MXPA04004498A (es) Derivados de n-adamantilmetil e intermediarios como composiciones farmaceuticas y procesos para su preparacion.
DE60105785D1 (de) Halogenierte triphenylethylene derivate als selektive östrogenrezeptormodulatoren
MXPA01008347A (es) Compuestos quimicos.
IL157651A0 (en) N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
AU5319101A (en) Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
IL153147A0 (en) Phospholipid derivatives of valporic acid and mixtures thereof
BRPI0412636A (pt) imidazopirimidinas substituìdas para a prevenção e tratamento de cáncer
TW200716566A (en) Prokineticin 2 receptor antagonists
WO2003027061A3 (en) Muscarinic agonists
GB0425548D0 (en) Radiolabelled ligands
MXPA04006113A (es) Derivados de triazoloquinolina utiles como ligandos receptores de adenosina.
TNSN03090A1 (fr) Derives d'ethers phenyliques d'heterocyclyle servant d' inhibiteurs selectifs de reabsorption de serotonine